The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

The company recently reported its third-quarter 2024 financial results, highlighting significant progress in its drug pipeline projects and key ... The company also finalized a collaboration agreement ...

Shares in global vaccine makers and drugmakers fell on Friday after U.S. President-elect Donald Trump picked Robert F.

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The banks have been quietly celebrating. The oil and gas giants are preparing fresh investment plans. The tech giants have ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...

Some school districts, including MSCS, have what's called a self-funded health plan. That means the employer pays for ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by ...